Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
| dc.contributor.author | Saei, A. | |
| dc.contributor.author | Eichhorn, Pieter | |
| dc.date.accessioned | 2018-12-13T09:14:30Z | |
| dc.date.available | 2018-12-13T09:14:30Z | |
| dc.date.created | 2018-12-12T02:47:06Z | |
| dc.date.issued | 2018 | |
| dc.identifier.citation | Saei, A. and Eichhorn, P. 2018. Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma. Molecular and Cellular Oncology. 5 (5). | |
| dc.identifier.uri | http://hdl.handle.net/20.500.11937/72815 | |
| dc.identifier.doi | 10.1080/23723556.2018.1497862 | |
| dc.description.abstract |
© 2018, © 2018 The Author(s). Published by Taylor & Francis. Response to targeted therapies is limited by the activation or inhibition of feedback loops. Here we report the ubiquitin specific peptidase 28/F-box WD repeat-containing protein 7 (USP28/FBW7) complex functions as a negative regulator of mitogen-activated protein kinase (MAPK) pathway by targeting v-raf murine sarcoma viral oncogene homolog B (BRAF) for degradation, a process which is lost in a large proportion of BRAF mutant melanoma patients, resulting in resistance to BRAF inhibitor therapies. | |
| dc.title | Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma | |
| dc.type | Journal Article | |
| dcterms.source.volume | 5 | |
| dcterms.source.number | 5 | |
| dcterms.source.issn | 2372-3556 | |
| dcterms.source.title | Molecular and Cellular Oncology | |
| curtin.department | School of Pharmacy and Biomedical Sciences | |
| curtin.accessStatus | Fulltext not available |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||